Market
Additional ₩100 billion purchase brings this year’s total to ₩500 billion Decision to be made next year after comparing immediate cancellation with higher dividends

Celltrion has decided to buy an additional ₩100 billion worth of treasury shares, bringing the value of its share-buyback decisions this year to a cumulative ₩500 billion. However, it did not commit to immediately canceling the shares in this purchase, deferring the decision until next year’s annual shareholders meeting.
Celltrion said in a regulatory filing on the 26th that it had decided to acquire 514,404 common shares, worth about ₩100 billion, through open-market purchases. The acquisition period will run for three months, from the 27th through Jan. 26, 2027.
This is the company’s fifth share-buyback decision this year, following those in April, May, August and September. The board has resolved to buy a total of 2,649,666 shares this year, worth ₩500 billion.
Rather than immediately proceeding with cancellation of the shares in this purchase, the company said it would gather shareholder opinions at its annual shareholders meeting in March 2027 and then decide between canceling the shares and increasing cash dividends.
The decision to delay cancellation reflects the company’s medium- to long-term policy of returning one-third of consolidated net income to shareholders. Immediate cancellation of treasury shares would permanently reduce capital, limiting flexibility to fund clinical trials for new pipelines, factory expansions and mergers and acquisitions (M&A).
By contrast, the company can support the share price by reducing the number of shares in circulation through open-market purchases, then adjust the balance between cash dividends and share cancellations once annual results and free cash flow are finalized at year-end. This could meet shareholder demands for returns while controlling cash outflows.
Business results show clear growth in scale. The company posted preliminary consolidated revenue of ₩1.5 trillion and operating profit of ₩510 billion in the third quarter of this year, setting quarterly records for both.
The results reflect stable cash generation from established flagship drugs such as Remsima and Truxima, alongside the global prescription uptake of Zymfentra (the U.S. brand name for Remsima SC) and the accelerating penetration of overseas markets by newer biosimilar products, including Omlyclo and Steqeyma.
Even so, with the share price remaining in a range of about ₩190,000 to ₩200,000 for an extended period, management opted for repeated open-market purchases to counter what it sees as the market’s undervaluation of the company relative to its earnings power.
Neither the market nor shareholders are uniformly supportive. Buybacks that leave shares in treasury could create potential overhang risks in the future, including stock-based compensation or the issuance of exchangeable bonds.
Some minority shareholders have continued to call for the company to make cancellation of 100% of acquired shares standard practice, rather than focusing on the size of the buyback. If the company reduces the proportion of shares canceled at next year’s annual meeting, citing increased dividends, it could face shareholder opposition.
Celltrion’s cumulative ₩500 billion in treasury-share purchases may provide short-term support for the share price, but a lasting revaluation of the company’s worth will depend directly on whether the shares are ultimately canceled. At the shareholders meeting next March, management’s decision on whether to cancel the shares or use them as an alternative to cash dividends is expected to test the sincerity of its shareholder-return policy.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss